GRADIAN II: Marketing to Multiple Stakeholders in a Complicated Field

THE PROBLEM/SOLUTION SPACE

Of the more than 230 million major surgical procedures performed worldwide each year, \(^1\) roughly 15 percent are completed with substandard anesthesia. \(^2\) This problem is particularly prevalent in developing countries, where hospitals often lack adequate infrastructure and equipment to perform safe anesthesia procedures. Although many facilities either purchase or receive donations of conventional anesthesia machinery used in hospitals in more developed countries, these devices are often inappropriate for the realities of low-resource surgical settings. According to some estimates, hospitals in developing regions experience an average of 18 power outages per month. \(^3\) They also face regular
shortages of compressed medical oxygen. Either of these problems will cause conventional anesthesia machines to shut down, creating devastating consequences for patients. Moreover, when conventional equipment malfunctions or breaks, hospitals in low-income settings frequently cannot get replacement parts and/or have no one qualified to perform the necessary repairs.

ABOUT GRADIAN AND THE UAM

In 1986, Dr. Paul Fenton, a British anesthesiologist, accepted a position as Head of the Department of Anesthesia at a busy teaching hospital in Blantyre, Malawi. Over the 15 years he spent working in that environment, he gained extended exposure to the many challenges that surgeons and anesthesiologists face in low-resource settings. After observing too many unnecessary injuries and deaths caused by surgeries that were interrupted or canceled due to the unavailability of anesthesia, Fenton designed a machine that could deliver safe, reliable anesthesia even in the midst of a power outage. The device, which he called the Universal Anaesthesia Machine (UAM), also generated its own oxygen from an integrated oxygen concentrator, which eliminated reliance on expensive cylinder or pipeline gas. If no electricity or other source of oxygen was available, the UAM defaulted to room air and always included oxygen monitoring to ensure the safety of the gas mixture.

After testing the UAM at his hospital in Malawi, Fenton sought to expand production. However, it took him more than a decade to line up the funding and support necessary to bring the idea to market. In 2009, Fenton joined forces with the Nick Simons Foundation, a private philanthropy supporting the Nick Simons Institute, which trained health workers to address needs in remote areas of Nepal. The foundation provided seed funding to further develop and test the UAM. Based on the positive results of those studies in the U.K. and Nepal, the Nick Simons Foundation spun out an organization it called Gradian Health Systems to produce and commercialize the UAM on a global basis.

Gradian was established as a wholly-owned subsidiary of the foundation. Structurally, it operated as a nonprofit, selling the UAM at its manufacturing cost so that sales and production of the device would become self-sustaining and scalable within several years. With philanthropic funding from the foundation, the company could underwrite the cost of end-user training at installation and a full after-sales service program. This structure was in line with the Nick Simons Foundation’s broader goals and Gradian’s specific mission, “to improve access to safe surgery and perioperative care by providing technology, service, and training to strengthen anesthesia capabilities.”

ONE CHALLENGE: MARKETING TO MULTIPLE STAKEHOLDERS IN A COMPLICATED FIELD

Gradian’s UAM faced two primary forms of competition. First, as Erica Frenkel, Director of Business Strategy, explained, “We compete against conventional anesthesia machines that are designed for operating theaters in developed settings. That means they’re reliant on electricity and compressed oxygen.” Even though this equipment was often not well suited to operating rooms in developing countries, several major medical device manufacturers had released basic models of their conventional machines in an effort to penetrate facilities in select geographies. “They’re coming out pretty aggressively in certain emerging markets,” Frenkel noted. The second type of competition came from other products, like the UAM, that were designed specifically for low-resource environ-
ments. “There’s really only one other company that makes another anesthesia machine that can be used in any circumstances,” she said. “Right now,” Frenkel summarized, “we’re seeing both kinds of competition. When a hospital or Ministry of Health needs to purchase an anesthesia machine, they’re looking at products across the board.”

Gradian generally was perceived as a good value in both product categories—the company offered a high-quality product at a competitive price. The UAM was CE certified and manufactured according to ISO quality standards. Gradian further distinguished the product from other companies working in the space through its commitment to comprehensive training and service, made possible by funding from the foundation.

The challenge was that Gradian’s small team had to market and sell the UAM to four distinct but interconnected stakeholder groups: users, hospitals, Ministries of Health, and donor organizations. The direct users of the product were the anesthesia providers who, in the developing world, were often not medical doctors. Instead, they were mid-level health care practitioners with specialized (although sometimes minimal) training in basic anesthesia delivery. These providers personally experienced the challenges created by the unreliable and unsafe equipment used in low-resource operating rooms. They were perhaps the easiest to convince of the UAM’s benefits but, as Frenkel pointed out, “They’re not the ones with the resources or decision-making power.” Those with the ability to make purchasing decisions resided at the hospital or Ministry level. However, a significant percentage of facilities and Ministries in the developing world were severely resource constrained, with operating budgets that could not accommodate regular capital investments. To acquire new equipment, such as anesthesia machines, many hospitals depended on nongovernmental organizations (NGOs) or international donor organizations to make these purchases. Decision makers within these organizations were furthest from the problem and sometimes lacked adequate information about the needs and constraints of the facilities they intended to serve. “The users and hospitals that know what they need are often not even involved in the decision-making process for the equipment that they’re going to get,” Frenkel said.

Complicating matters further, Gradian realized that the timing of anesthesia machine sales was important. “A hospital may buy one anesthesia machine this year and not purchase another for three years or more. So how do we identify and reach these folks before they make a decision?” Frenkel questioned.

Gradian had managed to get sales of the UAM off the ground mostly through referrals. “To date I would say our marketing has been primarily word of mouth,” Frenkel stated. “We have bid on a couple of tenders. But so far we’ve really relied on NGOs that have heard about the product and come to us, or we’ve ‘cold called’ them and it has just worked out. But clearly that’s not a scalable marketing plan.” Gradian needed a comprehensive strategy for tackling these challenges.

THE SOLUTION: DEVELOPING A COORDINATED, TARGETED MARKETING PLAN
In building its marketing strategy, Gradian decided that it was essential to reach all four stakeholder groups through a coordinated, yet targeted approach. Ideally, anesthesia providers would report to hospitals what they required; and hospitals, in turn, would pass
this information along to their donors who would use it to make their purchasing decisions. To begin moving toward this optimal model, the Gradian team would pursue a multi-part plan:

**Publish Meaningful Results**
As a top priority, Gradian would continue to conduct field studies of the UAM in collaboration with well-known, respected partners. For example, said Frenkel, “Johns Hopkins University is doing a study in its simulation lab in Baltimore, as well as in the field in Sierra Leone.” Gradian, which sometimes provided funding for the studies, insisted that they be conducted according to the highest scientific standards so that the results would be publishable in peer-reviewed journals. “We see that as a really important component of generating credibility,” Frenkel commented. All four of Gradian’s target stakeholder groups responded favorably to the availability of positive scientific data about the UAM and its benefits. “The studies are really just an extension of our work,” she added, “but they provide an invaluable way to get information into the public domain.”

**Build a Network of Key Opinion Leaders**
In parallel, the company would actively seek to expand its network of “champions”—highly respected users and hospital personnel who had direct experience with the value that the UAM delivered—in Gradian’s target geographies. These advocates were unpaid, but passionate about improving anesthesia safety in their countries. As such, they could be engaged to answer questions about the UAM and share their experiences with other users and hospitals, either on their own or at Gradian’s request. As Frenkel put it, “It’s very influential and boosts our credibility in the sales process when we’re not the ones saying that it’s a great machine.” Moreover, with a small team, Gradian could not be everywhere at once. “Our champions become our spokespeople, or an extension of us on the ground,” she added.

**Connect with Users Through Conferences and Professional Societies**
Another way that Gradian would involve users was to engage with them through medical conferences and professional society activities. “Even though their voices are quiet in the grand cacophony of bureaucratic decisions like these, the end users need to be heard,” Frenkel explained. “We certainly can’t go to every hospital in Africa,” she continued, “but through conferences and events we can reach large numbers of potential users.” For instance, Gradian had recently attended the conference of the Kenyan Society of Anaesthesiologists, where it was able to demonstrate the UAM to numerous anesthesia providers from the area. The team’s hope was that these users would start asking for the device when they returned to the hospitals where they worked. Gradian also used these interactions as a way to gather user feedback. “They help us understand the anesthesia community’s needs and interests,” Frenkel stated.

**Develop Targeted Marketing Collateral**
While all four constituencies stood to benefit from the UAM, each one had slightly different needs or “pain points” that the device would help address. The Gradian team worked to carefully understand the differences between its stakeholders’ points of view and then created marketing messages and materials that were tailored to each group “We developed a whole cadre of collateral that we used to speak to the different constituen-
cies,” said Frenkel. These materials were used to broadly raise awareness among users, hospitals, Ministries of Health, and governments/NGOs.

**Make the Most of Large-Scale Tenders**

In an effort to win more contracts for large-scale government and NGO orders, Gradian invested significant time and energy into better understanding the tender process and how it could optimally present the UAM in its proposals. “Part of it is understanding how the decision-making processes work for these major organizations,” Frenkel said. Another key aspect was raising awareness among these entities that affordable, appropriate technologies like the UAM even existed. To assist the company in this area, Gradian hired an outside consultant “to help us learn how to really speak to these types of organizations,” she noted.

**Create a Database of Donor Organizations**

To reach high-volume purchasers outside the tender process, Gradian planned to develop a list of the wide variety of organizations that made purchasing decisions for individual hospitals. For example, “In Malawi, we targeted a number of organizations that we had worked with, and in Uganda we’re starting to get a sense of organizations that train users but also fund equipment,” Frenkel said. The Gradian team gathered information about these organizations and also started tracking what it could about their purchasing cycles so that a team member could approach them at an appropriate time. “The idea is to get ahead of the organizations, before they make a decision about anesthesia equipment, so we can make them aware of the UAM, begin a dialog, and answer their questions,” she explained.

In 2012, Gradian was implementing this approach to help the company address its marketing challenges. “It’s like a huge knot we’re trying to untangle,” Frenkel described. “I wouldn’t say by any stretch of the imagination that we’ve solved it, but we’re working on it.” So far, the early phases of this plan had enabled Gradian to expand the sites where the UAM was being used from 2 to 11 countries.

### NOTES

3. Ibid.
4. Ibid.
7. Ibid.
8. All quotations are from an interview with Erica Frenkel conducted by the authors unless otherwise cited.